vTv Therapeutics (VTVT) Insider Akkaraju Buys $210K of Stock
Insider buying activity continues as Srinivas Akkaraju acquires 6,000 shares of VTVT.
Reviewed by automated data checks against the source filing. How we make and check alerts
Srinivas Akkaraju bought 6,000 shares of vTv Therapeutics Inc. ($VTVT) at an average price of $35.08, worth about $210,480, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $VTVT is down 1.5% after 1 week, down 11.6% after 1 month and down 24.3% to date (from the $35.08 close on Jun 26, 2026).
VTVT
vTv Therapeutics Inc.
Key Points
- Srinivas Akkaraju bought 6,000 shares of VTVT at $35.08 each, totaling $210,480 on June 26, 2026.
- Shares of VTVT traded near $36.27 on Tuesday, with analysts setting bullish price targets up to $67.
- Institutional interest includes Millennium Management opening a new position with 206,288 shares, valued at $8.18 million.
Get $VTVT trade alerts by text
We text you when insiders, Congress or big funds trade $VTVT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated vTv Therapeutics Inc. alert may contain errors. Disclosures
Srinivas Akkaraju recently made a purchase of 6,000 shares in VTVT at a price of $35.08 per share, totaling $210,480. This transaction took place on June 26, 2026, and was not part of a pre-planned trading program.
Insider Buying and Selling at vTv Therapeutics Inc.
On June 26, 2026, several insiders, including Srinivas Akkaraju, Anne Phillips, and Fahed Al-Marzooqi, each acquired 6,000 shares of VTVT at $35.08 per share. Additionally, Paul Sekhri, the President, CEO, and Executive Chairperson, purchased 140,000 shares at $36.92 on February 17, 2026.
Other Institutional Activity in VTVT
In recent institutional activity, Millennium Management LLC opened a new position in VTVT, acquiring 206,288 shares valued at approximately $8.18 million. FMR LLC reduced its holdings by 8,465 shares, bringing its total to 260,391 shares worth about $10.33 million, marking a 3.1% decrease. Samsara Biocapital, LLC maintained its position with 298,496 shares, valued at $11.84 million, while Trails Edge Capital Partners, LP significantly reduced its stake by 91,422 shares, a 39.6% decrease, holding 139,578 shares valued at $5.54 million.
vTv Therapeutics Inc. Stock Up 14.1%
Shares of VTVT traded near $36.27 on Tuesday. The stock has seen considerable interest, with a 52-week low of $30.00 and a high of $42.00. Institutional movements and insider buying suggest active interest in the stock, while analysts remain optimistic.
Analysts Set New Price Targets
Analyst sentiment towards VTVT remains positive. On March 12, 2026, Evercore ISI Group initiated coverage with a buy rating and a $44 price target. BTIG maintained its buy rating with a $49 target on January 27, 2026. Roth Capital and TD Cowen also initiated buy ratings earlier in the year, with targets of $58 and $67, respectively.
Bottom Line
Srinivas Akkaraju's recent purchase of VTVT shares highlights ongoing insider interest in the company. Analysts are optimistic, with several firms setting high price targets, reflecting confidence in VTVT's potential. As always, remember that insider trading reports and analyst ratings are backward-looking and may not represent current conditions.
Related Filing Alerts
Source: Srinivas Akkaraju's Form 4 filing on $VTVT (Jun 26, 2026). Find the original filing: VTVT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts